- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01342302
An Online Psychoeducational Intervention for Young Women With Breast Cancer and Their Partners (OPIC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Women diagnosed with breast cancer at or before the age of 40 experience greater distress and poorer quality of life than women diagnosed later in life. In addition to having to cope with the range of issues common to all women with breast cancer, young women face unique challenges such as loss of fertility, concerns for young children, and interruptions to early-stage careers. The presence of adequate social support is a mitigating factor for distress in young women, and spousal support in particular has been shown to play a crucial and distinctive role in determining how well a woman adjusts to breast cancer. Unfortunately, the evidence suggests well-spouses are significantly distressed themselves, and often fall short in their attempts to meet the needs of their ill partners despite generally good intentions. Consequently, researchers have recommended that psychosocial interventions be geared to couples. However, traditional counseling interventions may not appeal to younger couples with numerous responsibilities and time constraints.
The purpose of this study is to examine the feasibility, process, and outcomes of an innovative online intervention tailored to the unique needs of young women and their partners. The primary goal is to improve partners' relationship functioning and capacity to work together as a team in relation to the illness. The secondary goal is to combat feelings of isolation by creating a community of similarly affected couples. The intervention will be delivered via a professionally moderated, password-protected website and entail: Information relevant to young couples with breast cancer; structured, interactive learning modules; and a discussion board. The online modality is particularly suited to the younger demographic targeted by this project because of its familiarity, comfort, convenience, and flexibility.
A non-randomized, repeated measures analysis of variance design will be used to test the intervention. Seventeen couples will be recruited within the Greater Toronto Area. Questionnaires assessing relationship functioning, psychological adjustment, and quality of life will be administered to participants at baseline and at completion of the 7-week program. Qualitative data from the website and treatment satisfaction questionnaire will be analyzed thematically in order to improve the intervention and its delivery.
The potential for this online intervention to fill a void in support options available to both young women with breast cancer and their partners is vast. Following completion of the project, not only will there be a demonstrable product in the website, but the investigators will have the knowledge with which to further test the intervention in a RCT. The ultimate impact of the proposed project will be the creation of an accessible, cost-effective, empirically validated tool that could help to improve the quality of life of all young couples coping with breast cancer, regardless of geographic location, in the years to come.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Odette Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- woman has received a diagnosis of breast carcinoma within the last 18 months at any point in her treatment trajectory.
- Women must be free of known local recurrence or metastatic disease at the time of enrolment.
- Patients will have been 40 years of age or younger when diagnosed.
- Partners must be 45 years of age or younger at the time of diagnosis. - Couples must be heterosexual, and married, cohabitating, or engaged. - Participants must be fluent in English with the ability to read and write in English.
- All participants will require convenient access to a computer with internet connection.
Exclusion Criteria:
- All participants will be screened for mental illness that would interfere with their capacity to benefit from the program (e.g., suicidality, psychotic disorders, substance abuse) and excluded on this basis.
- Couples who plan to participate in couple or individual counselling during the 7-week study duration will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Couples Intervention
Single arm study design
|
Intervention delivered on line
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Dyadic Adjustment Scale (DAS) scores from pre (0 weeks) to post-treatment (7 weeks)
Time Frame: pre-treatment (0 weeks) and immediate post-treatment (7 weeks)
|
The DAS assesses couple's level of relationship satisfaction.
The DAS will be used to assess change in couples' level of relationship satisfaction following participation in the Couplelinks program over a 7 week period, from pre-treatment (0 weeks) to post-treatment (7 weeks).
|
pre-treatment (0 weeks) and immediate post-treatment (7 weeks)
|
|
Change in Personal Assessment of Intimacy in Relationships scale scores from pre (0 weeks) to post-treatment (7 weeks)
Time Frame: pre-treatment (0 weeks) and immediate post-treatment (7 weeks)
|
The Personal Assessment of Intimacy in Relationships scale assesses the degree of feelings of intimacy between partners.
This primary outcome measure will be used to assess changes in the degree of the feelings of intimacy between partners following participation in the Couplelinks program over a 7 week period, from pre-treatment (0 weeks) to post-treatment (7 weeks).
|
pre-treatment (0 weeks) and immediate post-treatment (7 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mental Psychological Development Questionnaire (MPDQ)
Time Frame: Pre-treatment (0 weeks) and immediate post-treatment (12 weeks).
|
The MPDQ assesses individual psychological adjustment.
|
Pre-treatment (0 weeks) and immediate post-treatment (12 weeks).
|
|
Mental Health Inventory (MHI)
Time Frame: pre-treatment (0 weeks) and post-treatment (7 weeks)
|
The MHI assesses individual psychological adjustment.
|
pre-treatment (0 weeks) and post-treatment (7 weeks)
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: pre-treatment (0 weeks) and immediate post-treatment (7 weeks)
|
The HADS assesses individual psychological adjustment.
|
pre-treatment (0 weeks) and immediate post-treatment (7 weeks)
|
|
Functional Assessment of Cancer Therapy-Breast (FACT-B)
Time Frame: pre-treatment (0 weeks) and immediate post-treatment (7 weeks
|
The FACT-B assesses women's individual physical and psychological adjustment to breast cancer treatment.
|
pre-treatment (0 weeks) and immediate post-treatment (7 weeks
|
|
Breast Cancer and Relationship Measure
Time Frame: pre-treatment (0 weeks) and immediate post-treatment (7 weeks
|
This measure assesses the impact of breast cancer on couple mutuality.
|
pre-treatment (0 weeks) and immediate post-treatment (7 weeks
|
|
Treatment Expectancy and Motivation Measure (TEMM)
Time Frame: pre-treatment (0 weeks)
|
The TEMM assesses the degree to which individuals believe that the treatment will be helpful to them prior to starting the treatment.
|
pre-treatment (0 weeks)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Karen Fergus, PhD, Toronto Sunnybrook Regional Cancer Centre
- Study Director: Debbie McLeod, PhD, RN, Cancer Care Program, Nova Scotia Cancer Centre
- Study Director: Ellen Warner, MD, Toronto Sunnybrook Regional Cancer Centre
- Study Director: Sandra Gardner, PhD, Toronto Sunnybrook Regional Cancer Centre
- Study Director: Margaret Fitch, RN, Toronto Sunnybrook Regional Cancer Centre
- Study Director: Barbara Fitzgerald, RN, Princess Margaret Hospital, Canada
- Study Director: Leeat Granek, PhD, Toronto Sunnybrook Regional Cancer Centre
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200-2008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
Clinical Trials on Psychosocial Intervention for Couples
-
Sykehuset Innlandet HFNorwegian Medical AssociationCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Terminated
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
University of Notre DameEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingBehavior, InfantUnited States
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.RecruitingCaregiving for CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
University of MichiganUniversity of California, San Francisco; Human Sciences Research CouncilActive, not recruitingHuman Immunodeficiency VirusSouth Africa
-
University of WashingtonNational Cancer Institute (NCI)Completed
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.Not yet recruitingPost-traumatic Stress SymptomsUnited States
-
Pakistan Institute of Living and LearningThe Hincks-Dellcrest CentreCompletedDepression | Maternal DepressionPakistan